🩺 Nursing Notes

Pharmacokinetics (ADME)

A
Absorption

How drug enters circulation. Affected by route, food, pH, blood flow.

D
Distribution

Drug movement to tissues. Affected by protein binding, lipid solubility, BBB.

M
Metabolism

Primarily liver (CYP450 enzymes). First-pass effect reduces oral bioavailability.

E
Excretion

Primarily kidneys. Renal/hepatic impairment → dose adjustments required.

Cardiovascular Drugs

ClassExamplesUseKey Nursing Considerations
Beta-BlockersMetoprolol, Atenolol, CarvedilolHTN, HF, angina, arrhythmiasMonitor HR & BP; do not abruptly stop; assess for bradycardia
ACE InhibitorsLisinopril, Enalapril, RamiprilHTN, HF, DM nephropathyMonitor for dry cough, hyperkalemia, angioedema; check BUN/Cr
ARBsLosartan, Valsartan, CandesartanHTN, HF, DM nephropathyAlternative to ACE inhibitors (no cough); monitor K⁺ and renal function
Loop DiureticsFurosemide (Lasix), BumetanideEdema, HF, HTNMonitor I&O, daily weight, electrolytes (↓K⁺, ↓Na⁺, ↓Mg²⁺)
DigoxinDigoxinHF, A-fib rate controlNarrow therapeutic index (0.5–2 ng/mL); assess apical HR; toxicity signs: nausea, visual changes, bradycardia
StatinsAtorvastatin, Rosuvastatin, SimvastatinHyperlipidemia, CV risk reductionMonitor LFTs; assess for myopathy/rhabdomyolysis (muscle pain, ↑CK)

Anticoagulants & Antiplatelets

DrugMechanismMonitorReversal Agent
Heparin (UFH)Activates antithrombin III → inhibits thrombin & factor XaaPTT (1.5–2.5× normal), platelets (HIT risk)Protamine sulfate
WarfarinInhibits vitamin K–dependent clotting factors (II, VII, IX, X)INR (therapeutic range varies by indication)Vitamin K, FFP, PCC
Enoxaparin (LMWH)Factor Xa inhibitor (primarily)Renal function; anti-Xa levels in special populationsProtamine sulfate (partial)
Rivaroxaban / ApixabanDirect factor Xa inhibitors (DOACs)Renal function; bleeding signsAndexanet alfa
DabigatranDirect thrombin inhibitor (DOAC)Renal function; bleeding signsIdarucizumab
AspirinIrreversible COX inhibition → ↓TXA₂Bleeding, GI upset, tinnitus (toxicity)No specific reversal; platelet transfusion

Diabetes Medications

ClassExamplesMechanismKey Nursing Points
Insulin (Rapid)Lispro, Aspart, GlulisineGlucose uptakeGive 0–15 min before meals; peak 1–2 hrs
Insulin (Long-Acting)Glargine, Detemir, DegludecBasal glucose controlDo NOT mix; no pronounced peak; give same time daily
MetforminMetformin↓Hepatic glucose productionHold before contrast dye; risk of lactic acidosis; check renal function
SulfonylureasGlipizide, Glyburide, Glimepiride↑Insulin secretionHypoglycemia risk; take with food
SGLT-2 InhibitorsEmpagliflozin, Dapagliflozin↑Urinary glucose excretionUTI/yeast infection risk; DKA risk (even with normal glucose); hold before surgery
GLP-1 AgonistsSemaglutide, Liraglutide↑Insulin, ↓glucagon, ↓appetiteNausea common; pancreatitis risk; weight loss benefit

Pain Management

  • WHO Analgesic Ladder – Step 1: Non-opioids (NSAIDs, acetaminophen) → Step 2: Mild opioids (tramadol, codeine) → Step 3: Strong opioids (morphine, oxycodone, fentanyl).
  • Opioid Side Effects – Respiratory depression (most dangerous), constipation (always prevent), nausea/vomiting, urinary retention, sedation.
  • Naloxone (Narcan) – Opioid reversal agent; short half-life (may need repeat doses or infusion); monitor for re-narcotization.
  • NSAIDs – Avoid in renal impairment, GI ulcers, and >3rd trimester pregnancy; monitor for GI bleeding.
  • Acetaminophen – Max 4 g/day (2 g/day in liver disease or heavy alcohol use); hepatotoxicity risk in overdose.

High-Alert Medications (ISMP)

  • Insulin — always double-check dose and type; use dedicated insulin syringes.
  • Anticoagulants — heparin infusion requires two-nurse verification of rate.
  • Concentrated electrolytes (KCl, NaCl >0.9%) — never give undiluted IV KCl (fatal arrhythmias).
  • Opioids — monitor respiratory rate, sedation level; have naloxone available.
  • Chemotherapy agents — use PPE; verify with pharmacist; strict extravasation protocols.
  • Neuromuscular blocking agents — must be on ventilator; keep reversal agents available.